- Home
- RDHL
as 07-26-2024 4:00pm EST
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
| Founded: | 2009 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 13.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 283.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $3.28 | Next Earning Date: | 08-15-2024 |
| Revenue: | $6,530,000 | Revenue Growth: | -87.51% |
| Revenue Growth (this year): | 224.9% | Revenue Growth (next year): | 82.69% |
Latest Redhill Biopharma Ltd. News
RDHL Breaking Stock News: Dive into RDHL Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
PR Newswire
18 days ago
RedHill Biopharma Terminates License Agreement for Aemcolo®
PR Newswire
2 months ago
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
MT Newswires
3 months ago
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib
PR Newswire
3 months ago
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
PR Newswire
3 months ago
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Simply Wall St.
4 months ago
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
PR Newswire
4 months ago
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Compare RDHL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RDHL Redhill Biopharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.